Literature DB >> 33429836

Dosimetric comparison of organs at risk in 5 different radiotherapy plans in patients with preoperatively irradiated rectal cancer.

Bekir Hakan Bakkal1, Ozlem Elmas.   

Abstract

BACKGROUND: Intensity-modulated radiotherapy (IMRT) is a widely used irradiation technique in rectal cancer patients. We aimed to compare 4 different IMRT plans with 3-dimensional conformal radiotherapy (3D-CRT) considering organs at risk (OARs) in patients with rectal carcinoma.
METHODS: This retrospective study included 27 rectal cancer patients who were irradiated preoperatively between January 2016 and December 2018. Five different plans (4-field 3D-CRT in 2 phases, 7-field IMRT in 2 phases, 9-field IMRT in 2 phases, 7-field simultaneous integrated boost [SIB] IMRT, and 9-field SIB IMRT) were generated for each patient. Comparison of 5 different plans according to bladder and bilateral femoral head mean doses, bladder V40, bilateral femoral head V40, and small bowel V35 values were evaluated.
RESULTS: Most of the OAR parameters significantly favored IMRT plans compared to the 3D-CRT plan. The largest difference was observed in bladder V40 values (reduction of V40 value up to 51.2% reduction) in favor of IMRT. In addition, SIB plans showed significantly better reduction in OARs than phase plans except for small bowel V35 values.
CONCLUSIONS: IMRT plans reduced almost all the OARs doses compared with the 3D-CRT plan in rectal cancer patients. Furthermore, SIB plans demonstrated lower OAR doses than the phase plans. IMRT techniques, especially SIB plans, reduce OAR doses and provide safer doses for the treatment of rectal carcinoma.
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

Entities:  

Mesh:

Year:  2021        PMID: 33429836      PMCID: PMC7793361          DOI: 10.1097/MD.0000000000024266

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.817


  31 in total

1.  Locally Advanced Rectal Cancer, What is the Standard of Care?

Authors:  Mehmet Sitki Copur; Whitney Wedel; Pornchai Jonglertham; Thomas Zusag; Adam Horn
Journal:  Oncology (Williston Park)       Date:  2020-01-15       Impact factor: 2.990

2.  Predicting grade 3 acute diarrhea during radiation therapy for rectal cancer using a cutoff-dose logistic regression normal tissue complication probability model.

Authors:  John M Robertson; Matthias Söhn; Di Yan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-08-06       Impact factor: 7.038

3.  Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries.

Authors:  Amy Berrington de Gonzalez; Rochelle E Curtis; Stephen F Kry; Ethel Gilbert; Stephanie Lamart; Christine D Berg; Marilyn Stovall; Elaine Ron
Journal:  Lancet Oncol       Date:  2011-04       Impact factor: 41.316

4.  Reduced acute bowel toxicity in patients treated with intensity-modulated radiotherapy for rectal cancer.

Authors:  Jason M Samuelian; Matthew D Callister; Jonathan B Ashman; Tonia M Young-Fadok; Mitesh J Borad; Leonard L Gunderson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-04-07       Impact factor: 7.038

5.  Organ-sparing Intensity-modulated radiotherapy for anal cancer using the ACTII schedule: a comparison of conventional and intensity-modulated radiotherapy plans.

Authors:  C J Brooks; Y K Lee; K Aitken; V N Hansen; D M Tait; M A Hawkins
Journal:  Clin Oncol (R Coll Radiol)       Date:  2012-09-14       Impact factor: 4.126

6.  The dose-volume relationship of small bowel irradiation and acute grade 3 diarrhea during chemoradiotherapy for rectal cancer.

Authors:  John M Robertson; David Lockman; Di Yan; Michelle Wallace
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-09-27       Impact factor: 7.038

7.  Dosimetric evaluation of intensity modulated radiotherapy and 4-field 3-d conformal radiotherapy in prostate cancer treatment.

Authors:  Bora Uysal; Murat Beyzadeoğlu; Omer Sager; Ferrat Dinçoğlan; Selçuk Demiral; Hakan Gamsız; Serdar Sürenkök; Kaan Oysul
Journal:  Balkan Med J       Date:  2013-03-01       Impact factor: 2.021

8.  Radiation Therapy for Cervical Cancer: Executive Summary of an ASTRO Clinical Practice Guideline.

Authors:  Junzo Chino; Christina M Annunziata; Sushil Beriwal; Lisa Bradfield; Beth A Erickson; Emma C Fields; KathrynJane Fitch; Matthew M Harkenrider; Christine H Holschneider; Mitchell Kamrava; Eric Leung; Lilie L Lin; Jyoti S Mayadev; Marc Morcos; Chika Nwachukwu; Daniel Petereit; Akila N Viswanathan
Journal:  Pract Radiat Oncol       Date:  2020-05-18

9.  A retrospective comparison of outcome and toxicity of preoperative image-guided intensity-modulated radiotherapy versus conventional pelvic radiotherapy for locally advanced rectal carcinoma.

Authors:  Chun-Ming Huang; Ming-Yii Huang; Hsiang-Lin Tsai; Ching-Wen Huang; Cheng-Jen Ma; Chih-Hung Lin; Chih-Jen Huang; Jaw-Yuan Wang
Journal:  J Radiat Res       Date:  2017-03-01       Impact factor: 2.724

10.  Comparison of volumetric-modulated arc therapy using simultaneous integrated boosts (SIB-VMAT) of 45 Gy/55 Gy in 25 fractions with conventional radiotherapy in preoperative chemoradiation for rectal cancers: a propensity score case-matched analysis.

Authors:  Hideomi Yamashita; Soichiro Ishihara; Hiroaki Nozawa; Kazushige Kawai; Tomomichi Kiyomatsu; Kae Okuma; Osamu Abe; Toshiaki Watanabe; Keiichi Nakagawa
Journal:  Radiat Oncol       Date:  2017-09-21       Impact factor: 3.481

View more
  1 in total

1.  The in-silico feasibility of dose escalated, hypofractionated radiotherapy for rectal cancer.

Authors:  Lynsey Devlin; Laura Grocutt; Bianca Hunter; Hiwot Chemu; Aileen Duffton; Alec McDonald; Nicholas Macleod; Philip McLoone; Sean M O'Cathail
Journal:  Clin Transl Radiat Oncol       Date:  2022-06-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.